摘要
目的通过检测血清miRNA-19b在早期(I和Ⅱ期)非小细胞肺癌(NSCLC)患者中的相对表达量,分析miRNA-19b在早期NSCLC诊断中的临床应用价值。方法应用qRT-PCR法检测100例早期NSCLC患者和50名体检正常人miRNA-19b的相对表达水平,通过ROC曲线判断其诊断价值,并与目前临床常用的肿瘤标志物癌胚抗原和细胞角蛋白比较。结果miRNA-19b在健康人对照中的表达量明显低于早期NSCLC,差异有显著统计学意义(P<0.001)。血清miRNA-19b在早期NSCLC中的敏感性(63.0%)显著高于癌胚抗原和细胞角蛋白的敏感性(4.0%和9.0%),差异均有显著统计学意义(P<0.001)。ROC曲线分析显示血清miRNA-19b在早期NSCLC中的辅助诊断价值明显好于癌胚抗原和细胞角蛋白。结论血清miRNA-19b在早期NSCLC辅助诊断中的价值显著优于癌胚抗原和细胞角蛋白,具有非常大的潜在临床应用价值。
Objective To explore the diagnostic value of miRNA-19b in non-small cell lung cancer(NSCLC)at early stage(stage I and stageⅡ).Methods The serum miRNA-19b level in 100 NSCLC patients of early stage and 50 healthy controls was examined by real-time quantitative PCR method.The ROC was used to analyze the sensitivity and specificity of serum miRNA-19b,and compared with CEA and cytokeratin.Results The level of serum miRNA-19b in healthy controls was significantly lower than that of NSCLC patients at early stage(P<0.001).The sensitivity and specificity of miRNA-19b in detecting early NSCLC were 63.0%and 98.0%.The sensitivity of miRNA-19b was higher than cytokeratin(9.0%)and CEA(4.0%)(P<0.001).The ROC showed that the diagnosis value of serum miRNA-19b in early NSCLC was superior to CEA and cytokeratin.Conclusion The diagnosis value of miRNA-19b in early NSCLC is better than CEA and cytokeratin,and has considerable value of potential clinical application.
作者
王达
马异峰
马尚
白万秋
居文福
时广利
WANG Da;MA Yi-feng;MA Shang;BAI Wan-qiu;JU Wen-fu;SHI Guang-li(Beijing Chest Hospital of Capital Medical University,Beijing101149,China)
出处
《临床肺科杂志》
2022年第8期1172-1175,共4页
Journal of Clinical Pulmonary Medicine
